This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Data Quantifying The Effects Of Opioid Use On Patient Care And Economic Outcomes Presented At Key Medical Meetings

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data that demonstrate opioid-related adverse drug events (ORADEs) following laparoscopic or open gastrointestinal (GI) surgeries increased total hospitalization costs by up to $12,724 and as much as doubled the length of hospital stay (LOS), depending on the type of surgical procedure performed. These findings were presented today during a poster session at the American Society of Colon and Rectal Surgeons (ASCRS) annual meeting in San Antonio, Texas.

Data from this regional retrospective analysis were drawn from 26 participating member hospitals of VHA Southeast (a regional office of VHA, Inc.), and included patients who underwent select laparoscopic or open GI surgeries and received opioid-based pain management regimens from January 2009 to December 2010. The research was supported by Pacira Pharmaceuticals, Inc.

Compared to patients who did not experience an ORADE:
  • Mean total hospitalization costs increased by $7,949 and $12,724 for patients experiencing an ORADE after a laparoscopic or open GI procedure, respectively.
  • Mean LOS was 1.5-1.9 times and 1.3-2.0 times longer for patients experiencing an ORADE after a laparoscopic or open GI procedure, respectively.

“These types of analyses continue to quantify the significant impact opioids have on our patients and the economics of hospital care in the United States,” said Dave Stack, president and CEO of Pacira Pharmaceuticals. “These data demonstrate that even in laparoscopic procedures, which are less invasive and intended to provide quicker patient recovery, opioid-related adverse events including nausea, vomiting, constipation, urinary retention and respiratory depression can significantly impact patient healing and hospital discharge.”

Additionally, new national data on the impact of ileus following postsurgical opioid use were presented during a poster session held today at the 17th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Washington, D.C. Ileus is a partial or complete blockage of the small and/or large intestine resulting in greatly impaired or lost bowel function. It is a complication significantly associated with abdominal procedures that can be exacerbated by opioid use.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs